Mitral valve disease-morphology and mechanisms

Nature Reviews Cardiology

Volumn 12, Issue 12, 2015, Pages 689-710

  Levine, Robert A ^a   Hagége, Albert A ^a   Judge, Daniel P ^a   Padala, Muralidhar ^a   Dal Bianco, Jacob P ^a   Aikawa, Elena ^a   Beaudoin, Jonathan ^a   Bischoff, Joyce ^a   Bouatia Naji, Nabila ^a   Bruneval, Patrick ^a   Butcher, Jonathan T ^a   Carpentier, Alain ^a   Chaput, Miguel ^a   Chester, Adrian H ^a   Clusel, Catherine ^a   Delling, Francesca N ^a   Dietz, Harry C ^a   Dina, Christian ^a   Durst, Ronen ^a   Fernandez Friera, Leticia ^a   Handschumacher, Mark D ^a   Jensen, Morten O ^a   Jeunemaitre, Xavier P ^a   Marec, Hervé Le ^a   Tourneau, Thierry Le ^a   Markwald, Roger R ^a   Mérot, Jean ^a   Messas, Emmanuel ^a   Milan, David P ^a   Neri, Tui ^a   Norris, Russell A ^a   Peal, David ^a   Perrocheau, Maelle ^a   Probst, Vincent ^a   Puceát, Michael ^a   Rosenthal, Nadia ^a   Solis, Jorge ^a   Schott, Jean Jacques ^a   Schwammenthal, Ehud ^a   Slaugenhaupt, Susan A ^a   Song, Jae Kwan ^a   Yacoub, Magdi H ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRILLIN 1; FILAMIN A; TRANSFORMING GROWTH FACTOR BETA;

BIOMECHANICS; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HISTOPATHOLOGY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MARFAN SYNDROME; MITRAL VALVE; MITRAL VALVE DISEASE; MITRAL VALVE PROLAPSE; MITRAL VALVE REGURGITATION; MORTALITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

HUMANS; MITRAL VALVE INSUFFICIENCY;

EID: 84947864890     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.161     Document Type: Review

References (318)

1. Nkomo, V. T. et al. Burden of valvular heart diseases: a population-based study. Lancet 368, 1005-1011 (2006).
2. Enriquez-Sarano, M. et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N. Engl. J. Med. 352, 875-883 (2005).
3. Judge, D. P., Markwald, R. R., Hagege, A. A. & Levine, R. A. Translational research on the mitral valve: from developmental mechanisms to new therapies. J. Cardiovasc. Transl. Res. 4, 699-701 (2011).
4. Roberts, R. Another chromosomal locus for mitral valve prolapse: close but no cigar. Circulation 112, 1924-1926 (2005).
5. Williams, T. H. & Jew, J. Y. Is the mitral valve passive flap theory overstated An active valve is hypothesized. Med. Hypotheses 62, 605-611 (2004).
6. Ng, C. M. et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J. Clin. Invest. 114, 1586-1592 (2004).
7. Barber, J. E. et al. Mechanical properties of myxomatous mitral valves. J. Thorac. Cardiovasc. Surg. 122, 955-962 (2001).
8. Barber, J. E., Ratliff, N. B., Cosgrove, D. M. 3rd, Griffin, B. P. & Vesely, I. Myxomatous mitral valve chordae. I: Mechanical properties. J. Heart Valve Dis. 10, 320-324 (2001).
9. Maslow, A. D., Regan, M. M., Haering, J. M., Johnson, R. G. & Levine, R. A. Echocardiographic predictors of left ventricular outflow tract obstruction and systolic anterior motion of the mitral valve after mitral valve reconstruction for myxomatous valve disease. J. Am. Coll. Cardiol. 34, 2096-2104 (1999).
10. Levine, R. A. & Schwammenthal, E. Ischemic mitral regurgitation on the threshold of a solution: from paradoxes to unifying concepts. Circulation 112, 745-758 (2005).
11. Chaput, M. et al. Mitral leaflet adaptation to ventricular remodeling: prospective changes in a model of ischemic mitral regurgitation. Circulation 120, S99-S103 (2009).
12. Chaput, M. et al. Mitral leaflet adaptation to ventricular remodeling: occurrence and adequacy in patients with functional mitral regurgitation. Circulation 118, 845-852 (2008).
13. Grande-Allen, K. J. et al. Mitral valve stiffening in end-stage heart failure: evidence of an organic contribution to functional mitral regurgitation. J. Thorac. Cardiovasc. Surg. 130, 783-790 (2005).
14. Schwammenthal, E. et al. Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: mismatch of posterior to anterior leaflet length and mobility. Circulation 98, 856-865 (1998).
15. Kim, D. H. et al. In vivo measurement of mitral leaflet surface area and subvalvular geometry in patients with asymmetrical septal hypertrophy: insights into the mechanism of outflow tract obstruction. Circulation 122, 1298-1307 (2010).
16. Hagege, A. A. et al. The mitral valve in hypertrophic cardiomyopathy: old versus new concepts. J. Cardiovasc. Transl. Res. 4, 757-766 (2011).
17. Dal-Bianco, J. P. & Levine, R. A. Anatomy of the mitral valve apparatus: role of 2D and 3D echocardiography. Cardiol. Clin. 31, 151-164 (2013).
18. Cooper, T. et al. Structural basis of cardiac valvar function. Arch. Surg. 93, 767-771 (1966).
19. Wit, A. L., Fenoglio, J. J. Jr, Hordof, A. J. & Reemtsma, K. Ultrastructure and transmembrane potentials of cardiac muscle in the human anterior mitral valve leaflet. Circulation 59, 1284-1292 (1979).
20. Nordrum, I. S. & Skallerud, B. Smooth muscle in the human mitral valve: extent and implications for dynamic modelling. APMIS 120, 484-494 (2012).
21. Sonnenblick, E. H., Napolitano, L. M., Daggett, W. M. & Cooper, T. An intrinsic neuromuscular basis for mitral valve motion in the dog. Circ. Res. 21, 9-15 (1967).
22. Marron, K. et al. Innervation of human atrioventricular and arterial valves. Circulation 94, 368-375 (1996).
23. Wit, A. L., Fenoglio, J. J. Jr, Wagner, B. M. & Bassett, A. L. Electrophysiological properties of cardiac muscle in the anterior mitral valve leaflet and the adjacent atrium in the dog. Possible implications for the genesis of atrial dysrhythmias. Circ. Res. 32, 731-745 (1973).
24. Fenoglio, J. J. Jr, Tuan Duc, P., Wit, A. L., Bassett, A. L. & Wagner, B. M. Canine mitral complex. Ultrastructure and electromechanical properties. Circ. Res. 31, 417-430 (1972).
25. Swanson, J. C. et al. Characterization of mitral valve anterior leaflet perfusion patterns. J. Heart Valve Dis. 18, 488-495 (2009).
26. Filip, D. A., Radu, A. & Simionescu, M. Interstitial cells of the heart valves possess characteristics similar to smooth muscle cells. Circ. Res. 59, 310-320 (1986).
27. Grande-Allen, K. J. et al. Glycosaminoglycans and proteoglycans in normal mitral valve leaflets and chordae: association with regions of tensile and compressive loading. Glycobiology 14, 621-633 (2004).
28. Itoh, A. et al. Active stiffening of mitral valve leaflets in the beating heart. Am. J. Physiol. Heart Circ. Physiol. 296, H1766-H1773 (2009).
29. Sacks, M. S. & Yoganathan, A. P. Heart valve function: a biomechanical perspective. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 362, 1369-1391 (2007).
30. Padala, M. et al. Mechanics of the mitral valve strut chordae insertion region. J. Biomech. Eng. 132, 081004 (2010).
31. Lim, K. O., Boughner, D. R. & Smith, C. A. Dynamic elasticity of human mitral valve chorade tendinease. Can. J. Physiol. Pharmacol. 55, 413-418 (1977).
32. Lim, K. O. & Boughner, D. R. Mechanical properties of human mitral valve chordae tendineae: variation with size and strain rate. Can. J. Physiol. Pharmacol. 53, 330-339 (1975).
33. Butcher, J. T. & Nerem, R. M. Valvular endothelial cells and the mechanoregulation of valvular pathology. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 362, 1445-1457 (2007).
34. Liu, A. C., Joag, V. R. & Gotlieb, A. I. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am. J. Pathol. 171, 1407-1418 (2007).
35. de Lange, F. J. et al. Lineage and morphogenetic analysis of the cardiac valves. Circ. Res. 95, 645-654 (2004).
36. Lincoln, J., Alfieri, C. M. & Yutzey, K. E. Development of heart valve leaflets and supporting apparatus in chicken and mouse embryos. Dev. Dyn. 230, 239-250 (2004).
37. Tao, G., Kotick, J. D. & Lincoln, J. Heart valve development, maintenance, and disease: the role of endothelial cells. Curr. Top. Dev. Biol. 100, 203-232 (2012).
38. von Gise, A. & Pu, W. T. Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circ. Res. 110, 1628-1645 (2012).
39. Hakuno, D. et al. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. J. Clin. Invest. 120, 2292-2306 (2010).
40. Lie-Venema, H. et al. Origin, fate, and function of epicardium-derived cells (EPDCs) in normal and abnormal cardiac development. Scientific World Journal 7, 1777-1798 (2007).
41. Wessels, A. et al. Epicardially derived fibroblasts preferentially contribute to the parietal leaflets of the atrioventricular valves in the murine heart. Dev. Biol. 366, 111-124 (2012).
42. Paruchuri, S. et al. Human pulmonary valve progenitor cells exhibit endothelial/mesenchymal plasticity in response to vascular endothelial growth factor-A and transforming growth factor-beta2. Circ. Res. 99, 861-869 (2006).
43. Aikawa, E. et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation 113, 1344-1352 (2006).
44. Fornes, P. et al. Correlation between clinical and histologic patterns of degenerative mitral valve insufficiency: a histomorphometric study of 130 excised segments. Cardiovasc. Pathol. 8, 81-92 (1999).
45. Shapero, K., Wylie-Sears, J., Levine, R. A., Mayer, J. E. Jr & Bischoff, J. Reciprocal interactions between mitral valve endothelial and interstitial cells reduce endothelial-to-mesenchymal transition and myofibroblastic activation. J. Mol. Cell. Cardiol. 80C, 175-185 (2015).
46. Timek, T. A. et al. Ablation of mitral annular and leaflet muscle: effects on annular and leaflet dynamics. Am. J. Physiol. Heart Circ. Physiol. 285, H1668-H1674 (2003).
47. Jensen, M. O. et al. Saddle-shaped mitral valve annuloplasty rings improve leaflet coaptation geometry. J. Thorac. Cardiovasc. Surg. 142, 697-703 (2011).
48. Salgo, I. S. et al. Effect of annular shape on leaflet curvature in reducing mitral leaflet stress. Circulation 106, 711-717 (2002).
49. Itoh, A. et al. Contribution of myocardium overlying the anterolateral papillary muscle to left ventricular deformation. Am. J. Physiol. Heart Circ. Physiol. 302, H180-H187 (2012).
50. Jensen, M. O. et al. Saddle-shaped mitral valve annuloplasty rings experience lower forces compared with flat rings. Circulation 118, S250-S255 (2008).
51. Rausch, M. K. et al. In vivo dynamic strains of the ovine anterior mitral valve leaflet. J. Biomech. 44, 1149-1157 (2011).
52. Grashow, J. S., Sacks, M. S., Liao, J. & Yoganathan, A. P. Planar biaxial creep and stress relaxation of the mitral valve anterior leaflet. Ann. Biomed. Eng. 34, 1509-1518 (2006).
53. Grashow, J. S., Yoganathan, A. P. & Sacks, M. S. Biaixal stress-stretch behavior of the mitral valve anterior leaflet at physiologic strain rates. Ann. Biomed. Eng. 34, 315-325 (2006).
54. Padala, M. et al. Saddle shape of the mitral annulus reduces systolic strains on the P2 segment of the posterior mitral leaflet. Ann. Thorac. Surg. 88, 1499-1504 (2009).
55. Niwa, K., Ikeda, F., Miyamoto, H., Nakajima, H. & Ando, M. Absent aortic valve with normally related great arteries. Heart Vessels 3, 104-107 (1987).
56. Gupta, V., Werdenberg, J. A., Blevins, T. L. & Grande-Allen, K. J. Synthesis of glycosaminoglycans in differently loaded regions of collagen gels seeded with valvular interstitial cells. Tissue Eng. 13, 41-49 (2007).
57. Ku, C. H. et al. Collagen synthesis by mesenchymal stem cells and aortic valve interstitial cells in response to mechanical stretch. Cardiovasc. Res. 71, 548-556 (2006).
58. Merryman, W. D. Insights into (the interstitium of) degenerative aortic valve disease. J. Am. Coll. Cardiol. 51, 1415 (2008).
59. Li, C. & Gotlieb, A. I. Transforming growth factor-beta regulates the growth of valve interstitial cells in vitro. Am. J. Pathol. 179, 1746-1755 (2011).
60. Balachandran, K. et al. Cyclic strain induces dual-mode endothelial-mesenchymal transformation of the cardiac valve. Proc. Natl Acad. Sci. USA 108, 19943-19948 (2011).
61. El-Hamamsy, I. et al. Rate of progression and functional significance of aortic root calcification after homograft versus freestyle aortic root replacement. Circulation 120, S269-S275 (2009).
62. Mahler, G. J., Farrar, E. J. & Butcher, J. T. Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. Arterioscler. Thromb. Vasc. Biol. 33, 121-130 (2013).
63. Kilner, P. J. et al. Asymmetric redirection of flow through the heart. Nature 404, 759-761 (2000).
64. Ro, R. et al. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve. J. Am. Coll. Cardiol. 64, 1984-1995 (2014).
65. Eriksson, J. et al. Semi-automatic quantification of 4D left ventricular blood flow. J. Cardiovasc. Magn. Reson. 12, 9 (2010).
66. Bolger, A. F. et al. Transit of blood flow through the human left ventricle mapped by cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 9, 741-747 (2007).
67. Markwald, R. R., Fitzharris, T. P. & Manasek, F. J. Structural development of endocardial cushions. Am. J. Anat. 148, 85-119 (1977).
68. Markwald, R. R., Norris, R. A., Moreno-Rodriguez, R. & Levine, R. A. Developmental basis of adult cardiovascular diseases: valvular heart diseases. Ann. N. Y. Acad. Sci. 1188, 177-183 (2010).
69. de Vlaming, A. et al. Atrioventricular valve development: new perspectives on an old theme. Differentiation 84, 103-116 (2012).
70. Hinton, R. B. & Yutzey, K. E. Heart valve structure and function in development and disease. Annu. Rev. Physiol. 73, 29-46 (2011).
71. Armstrong, E. J. & Bischoff, J. Heart valve development: endothelial cell signaling and differentiation. Circ. Res. 95, 459-470 (2004).
72. Norris, R. A. et al. Periostin regulates atrioventricular valve maturation. Dev. Biol. 316, 200-213 (2008).
73. Milgrom-Hoffman, M. et al. The heart endocardium is derived from vascular endothelial progenitors. Development 138, 4777-4787 (2011).
74. Puceat, M. Embryological origin of the endocardium and derived valve progenitor cells: from developmental biology to stem cell-based valve repair. Biochim. Biophys. Acta 1833, 917-922 (2013).
75. Inai, K., Norris, R. A., Hoffman, S., Markwald, R. R. & Sugi, Y. BMP-2 induces cell migration and periostin expression during atrioventricular valvulogenesis. Dev. Biol. 315, 383-396 (2008).
76. Wu, B. et al. Nfatc1 coordinates valve endocardial cell lineage development required for heart valve formation. Circ. Res. 109, 183-192 (2011).
77. Yang, J. H., Wylie-Sears, J. & Bischoff, J. Opposing actions of Notch1 and VEGF in post-natal cardiac valve endothelial cells. Biochem. Biophys. Res. Commun. 374, 512-516 (2008).
78. Sell, S. & Scully, R. E. Aging changes in the aortic and mitral valves. Histologic and histochemical studies, with observations on the pathogenesis of calcific aortic stenosis and calcification of the mitral annulus. Am. J. Pathol. 46, 345-365 (1965).
79. Pomerance, A. Ageing changes in human heart valves. Br. Heart J. 29, 222-231 (1967).
80. Pham, T. & Sun, W. Material properties of aged human mitral valve leaflets. J. Biomed. Mater. Res. A 102, 2692-2703 (2014).
81. Freed, L. A. et al. Prevalence and clinical outcome of mitral-valve prolapse. N. Engl. J. Med. 341, 1-7 (1999).
82. Waller, B. F. et al. Etiology of clinically isolated, severe, chronic, pure mitral regurgitation: analysis of 97 patients over 30 years of age having mitral valve replacement. Am. Heart J. 104, 276-288 (1982).
83. Freed, L. A. et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. J. Am. Coll. Cardiol. 40, 1298-1304 (2002).
84. Avierinos, J. F. et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 106, 1355-1361 (2002).
85. Procacci, P. M., Savran, S. V., Schreiter, S. L. & Bryson, A. L. Prevalence of clinical mitral-valve prolapse in 1169 young women. N. Engl. J. Med. 294, 1086-1088 (1976).
86. Flack, J. M. et al. Anthropometric and physiologic correlates of mitral valve prolapse in a biethnic cohort of young adults: the CARDIA study. Am. Heart J. 138, 486-492 (1999).
87. Levine, R. A. et al. Three-dimensional echocardiographic reconstruction of the mitral valve, with implications for the diagnosis of mitral valve prolapse. Circulation 80, 589-598 (1989).
88. Levine, R. A., Stathogiannis, E., Newell, J. B., Harrigan, P. & Weyman, A. E. Reconsideration of echocardiographic standards for mitral valve prolapse: lack of association between leaflet displacement isolated to the apical four chamber view and independent echocardiographic evidence of abnormality. J. Am. Coll. Cardiol. 11, 1010-1019 (1988).
89. Levine, R. A., Triulzi, M. O., Harrigan, P. & Weyman, A. E. The relationship of mitral annular shape to the diagnosis of mitral valve prolapse. Circulation 75, 756-767 (1987).
90. Otani, K. et al. Evidence of a vicious cycle in mitral regurgitation with prolapse: secondary tethering attributed to primary prolapse demonstrated by three-dimensional echocardiography exacerbates regurgitation. Circulation 126, S214-S221 (2012).
91. Dal-Bianco, J. P., Beaudoin, J., Handschumacher, M. D. & Levine, R. A. Basic mechanisms of mitral regurgitation. Can. J. Cardiol. 30, 971-981 (2014).
92. Slaugenhaupt, S. et al. Genetic mechanisms of mitral valve prolapse. Curr. Cardiovasc. Risk Rep. 2, 463-467 (2008).
93. Addetia, K., Mor-Avi, V., Weinert, L., Salgo, I. S. & Lang, R. M. A new definition for an old entity: improved definition of mitral valve prolapse using three-dimensional echocardiography and color-coded parametric models. J. Am. Soc. Echocardiogr. 27, 8-16 (2014).
94. Ling, L. H. et al. Early surgery in patients with mitral regurgitation due to flail leaflets: a long-term outcome study. Circulation 96, 1819-1825 (1997).
95. Ling, L. H. et al. Clinical outcome of mitral regurgitation due to flail leaflet. N. Engl. J. Med. 335, 1417-1423 (1996).
96. Carabello, B. A. The current therapy for mitral regurgitation. J. Am. Coll. Cardiol. 52, 319-326 (2008).
97. Grigioni, F. et al. Outcomes in mitral regurgitation due to flail leaflets a multicenter European study. JACC Cardiovasc. Imaging 1, 133-141 (2008).
98. Le Tourneau, T. et al. Right ventricular systolic function in organic mitral regurgitation: impact of biventricular impairment. Circulation 127, 1597-1608 (2013).
99. Urabe, Y. et al. Cellular and ventricular contractile dysfunction in experimental canine mitral regurgitation. Circ. Res. 70, 131-147 (1992).
100. Chiechi, M. A., Lees, W. M. & Thompson, R. Functional anatomy of the normal mitral valve. J. Thorac. Surg. 32, 378-398 (1956).
101. Rusted, I. E., Scheifley, C. H. & Edwards, J. E. Studies of the mitral valve. I. Anatomic features of the normal mitral valve and associated structures. Circulation 6, 825-831 (1952).
102. Ormiston, J. A., Shah, P. M., Tei, C. & Wong, M. Size and motion of the mitral valve annulus in man. I. A two-dimensional echocardiographic method and findings in normal subjects. Circulation 64, 113-120 (1981).
103. Gorgulu, S. et al. Influence of different echocardiographic imaging modes on the assessment of anterior mitral leaflet thickness. J. Heart Valve Dis. 14, 204-208 (2005).
104. Louie, E. K. et al. Transesophageal echocardiographic assessment of the contribution of intrinsic tissue thickness to the appearance of a thick mitral valve in patients with mitral valve prolapse. J. Am. Coll. Cardiol. 28, 465-471 (1996).
105. Marks, A. R., Choong, C. Y., Sanfilippo, A. J., Ferre, M. & Weyman, A. E. Identification of high-risk and low-risk subgroups of patients with mitral-valve prolapse. N. Engl. J. Med. 320, 1031-1036 (1989).
106. Grayburn, P. A. et al. Relation of echocardiographic morphology of the mitral apparatus to mitral regurgitation in mitral valve prolapse: assessment by Doppler color flow imaging. Am. Heart J. 119, 1095-1102 (1990).
107. Schwammenthal, E. et al. Dynamics of mitral regurgitant flow and orifice area. Physiologic application of the proximal flow convergence method: clinical data and experimental testing. Circulation 90, 307-322 (1994).
108. Enriquez-Sarano, M., Sinak, L. J., Tajik, A. J., Bailey, K. R. & Seward, J. B. Changes in effective regurgitant orifice throughout systole in patients with mitral valve prolapse. A clinical study using the proximal isovelocity surface area method. Circulation 92, 2951-295 (1995).
109. Chapman, D. W. The cumulative risks of prolapsing mitral valve. 40 years of follow-up. Tex. Heart Inst. J. 21, 267-271 (1994).
110. Avierinos, J. F., Detaint, D., Messika-Zeitoun, D., Mohty, D. & Enriquez-Sarano, M. Risk, determinants, and outcome implications of progression of mitral regurgitation after diagnosis of mitral valve prolapse in a single community. Am. J. Cardiol. 101, 662-667 (2008).
111. Lee, A. P. et al. Quantitative analysis of mitral valve morphology in mitral valve prolapse with real-time 3-dimensional echocardiography: importance of annular saddle shape in the pathogenesis of mitral regurgitation. Circulation 127, 832-841 (2013).
112. Jensen, M. O., Hagege, A. A., Otsuji, Y., Levine, R. A. & Leducq Transatlantic MITRAL Network. The unsaddled annulus: biomechanical culprit in mitral valve prolapse Circulation 127, 766-768 (2013).
113. Delling, F. N. & Vasan, R. S. Epidemiology and pathophysiology of mitral valve prolapse: new insights into disease progression, genetics, and molecular basis. Circulation 129, 2158-2170 (2014).
114. Delling, F. N. et al. Mild expression of mitral valve prolapse in the Framingham offspring: expanding the phenotypic spectrum. J. Am. Soc. Echocardiogr. 27, 17-23 (2014).
115. Nesta, F. et al. New locus for autosomal dominant mitral valve prolapse on chromosome 13: clinical insights from genetic studies. Circulation 112, 2022-2030 (2005).
116. Zuppiroli, A., Roman, M. J., O'Grady, M. & Devereux, R. B. A family study of anterior mitral leaflet thickness and mitral valve prolapse. Am. J. Cardiol. 82, 823-826 (1998).
117. Flameng, W., Meuris, B., Herijgers, P. & Herregods, M. C. Durability of mitral valve repair in Barlow disease versus fibroelastic deficiency. J. Thorac. Cardiovasc. Surg. 135, 274-282 (2008).
118. Matsumaru, I. et al. Clinical and pathological features of degenerative mitral valve disease: billowing mitral leaflet versus fibroelastic deficiency. Ann. Thorac. Cardiovasc. Surg. 20, 987-994 (2014).
119. Chandra, S. et al. Characterization of degenerative mitral valve disease using morphologic analysis of real-time three-dimensional echocardiographic images: objective insight into complexity and planning of mitral valve repair. Circ. Cardiovasc. Imaging 4, 24-32 (2011).
120. Anyanwu, A. C. & Adams, D. H. Etiologic classification of degenerative mitral valve disease: Barlow's disease and fibroelastic deficiency. Semin. Thorac. Cardiovasc. Surg. 19, 90-96 (2007).
121. Akhtar, S., Meek, K. M. & James, V. Ultrastructure abnormalities in proteoglycans, collagen fibrils, and elastic fibers in normal and myxomatous mitral valve chordae tendineae. Cardiovasc. Pathol. 8, 191-201 (1999).
122. Rabkin, E. et al. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 104, 2525-2532 (2001).
123. Rabkin-Aikawa, E., Farber, M., Aikawa, M. & Schoen, F. J. Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J. Heart Valve Dis. 13, 841-847 (2004).
124. Grande-Allen, K. J., Griffin, B. P., Ratliff, N. B., Cosgrove, D. M. & Vesely, I. Glycosaminoglycan profiles of myxomatous mitral leaflets and chordae parallel the severity of mechanical alterations. J. Am. Coll. Cardiol. 42, 271-277 (2003).
125. Dainese, L. et al. Fine characterization of mitral valve glycosaminoglycans and their modification with degenerative disease. Clin. Chem. Lab. Med. 45, 361-366 (2007).
126. Gupta, V. et al. Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valves. Cardiovasc. Pathol. 18, 191-197 (2009).
127. Mills, W. R. et al. Biomechanical and echocardiographic characterization of flail mitral leaflet due to myxomatous disease: further evidence for early surgical intervention. Am. Heart J. 148, 144-150 (2004).
128. Barlow, J. B. & Bosman, C. K. Aneurysmal protrusion of the posterior leaflet of the mitral valve. An auscultatory-electrocardiographic syndrome. Am. Heart J. 71, 166-178 (1966).
129. Carpentier, A. et al. Reconstructive surgery of mitral valve incompetence: ten-year appraisal. J. Thorac. Cardiovasc. Surg. 79, 338-348 (1980).
130. McKusick, V. A. Heritable Disorders of Connective Tissue (C. V. Mosby Company, 1972).
131. Disse, S. et al. Mapping of a first locus for autosomal dominant myxomatous mitral-valve prolapse to chromosome 16p11.2-p12.1. Am. J. Hum. Genet. 65, 1242-1251 (1999).
132. Freed, L. A. et al. A locus for autosomal dominant mitral valve prolapse on chromosome 11p15.4. Am. J. Hum. Genet. 72, 1551-1559 (2003).
133. Oceandy, D., Yusoff, R., Baudoin, F. M., Neyses, L. & Ray, S. G. Promoter polymorphism of the matrix metalloproteinase 3 gene is associated with regurgitation and left ventricular remodelling in mitral valve prolapse patients. Eur. J. Heart Fail. 9, 1010-1017 (2007).
134. Delling, F. N. et al. Familial clustering of mitral valve prolapse in the community. Circulation 131, 263-268 (2015).
135. Pini, R., Greppi, B., Kramer-Fox, R., Roman, M. J. & Devereux, R. B. Mitral valve dimensions and motion and familial transmission of mitral valve prolapse with and without mitral leaflet billowing. J. Am. Coll. Cardiol. 12, 1423-1431 (1988).
136. Devereux, R. B., Brown, W. T., Kramer-Fox, R. & Sachs, I. Inheritance of mitral valve prolapse: effect of age and sex on gene expression. Ann. Intern. Med. 97, 826-832 (1982).
137. Levine, R. A. & Slaugenhaupt, S. A. Molecular genetics of mitral valve prolapse. Curr. Opin. Cardiol. 22, 171-175 (2007).
138. Loardi, C. et al. Biology of mitral valve prolapse: the harvest is big, but the workers are few. Int. J. Cardiol. 151, 129-135 (2011).
139. Dietz, H. C. et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352, 337-339 (1991).
140. Pyeritz, R. E. & Wappel, M. A. Mitral valve dysfunction in the Marfan syndrome. Clinical and echocardiographic study of prevalence and natural history. Am. J. Med. 74, 797-807 (1983).
141. Taub, C. C. et al. Mitral valve prolapse in Marfan syndrome: an old topic revisited. Echocardiography 26, 357-364 (2009).
142. Montgomery, R. A. et al. Multiple molecular mechanisms underlying subdiagnostic variants of Marfan syndrome. Am. J. Hum. Genet. 63, 1703-1711 (1998).
143. Glesby, M. J. & Pyeritz, R. E. Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum. JAMA 262, 523-528 (1989).
144. Judge, D. P., Rouf, R., Habashi, J. & Dietz, H. C. Mitral valve disease in Marfan syndrome and related disorders. J. Cardiovasc. Transl. Res. 4, 741-747 (2011).
145. Habashi, J. P. et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312, 117-121 (2006).
146. Neptune, E. R. et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33, 407-411 (2003).
147. Isogai, Z. et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J. Biol. Chem. 278, 2750-2757 (2003).
148. Brooke, B. S. et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N. Engl. J. Med. 358, 2787-2795 (2008).
149. Cohn, R. D. et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 13, 204-210 (2007).
150. Geirsson, A. et al. Modulation of transforming growth factor-beta signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers. Circulation 126, S189-S197 (2012).
151. Loeys, B. L. et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat. Genet. 37, 275-281 (2005).
152. Lindsay, M. E. et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat. Genet. 44, 922-927 (2012).
153. Attias, D. et al. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation 120, 2541-2549 (2009).
154. van de Laar, I. M. et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat. Genet. 43, 121-126 (2011).
155. van de Laar, I. M. et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J. Med. Genet. 49, 47-57 (2012).
156. Habashi, J. P. et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 332, 361-365 (2011).
157. Holm, T. M. et al. Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332, 358-361 (2011).
158. Lindsay, M. E. & Dietz, H. C. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature 473, 308-316 (2011).
159. Monteleone, P. L. & Fagan, L. F. Possible X-linked congenital heart disease. Circulation 39, 611-614 (1969).
160. Kyndt, F. et al. Mapping of X-linked myxomatous valvular dystrophy to chromosome Xq28. Am. J. Hum. Genet. 62, 627-632 (1998).
161. Kyndt, F. et al. Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation 115, 40-49 (2007).
162. Aalberts, J. J. et al. Screening of TGFBR1, TGFBR2, and FLNA in familial mitral valve prolapse. Am. J. Med. Genet. A 164A, 113-119 (2014).
163. Nakamura, F., Stossel, T. P. & Hartwig, J. H. The filamins: organizers of cell structure and function. Cell Adh. Migr. 5, 160-169 (2011).
164. Zhou, A. X., Hartwig, J. H. & Akyurek, L. M. Filamins in cell signaling, transcription and organ development. Trends Cell. Biol. 20, 113-123 (2010).
165. Baldassarre, M. et al. Filamins regulate cell spreading and initiation of cell migration. PLoS ONE 4, e7830 (2009).
166. Norris, R. A. et al. Expression of the familial cardiac valvular dystrophy gene, filamin-A, during heart morphogenesis. Dev. Dyn. 239, 2118-2127 (2010).
167. Duval, D. et al. Valvular dystrophy associated filamin A mutations reveal a new role of its first repeats in small-GTPase regulation. Biochim. Biophys. Acta 1843, 234-244 (2014).
168. Feng, Y. et al. Filamin A (FLNA) is required for cell-cell contact in vascular development and cardiac morphogenesis. Proc. Natl Acad. Sci. USA 103, 19836-19841 (2006).
169. Stossel, T. P. et al. Filamins as integrators of cell mechanics and signalling. Nat. Rev. Mol. Cell Biol. 2, 138-145 (2001).
170. Sauls, K. et al. Developmental basis for filamin-A-associated myxomatous mitral valve disease. Cardiovasc. Res. 96, 109-119 (2012).
171. Grau, J. B., Pirelli, L., Yu, P. J., Galloway, A. C. & Ostrer, H. The genetics of mitral valve prolapse. Clin. Genet. 72, 288-295 (2007).
172. Padang, R., Bagnall, R. D. & Semsarian, C. Genetic basis of familial valvular heart disease. Circ. Cardiovasc. Genet. 5, 569-580 (2012).
173. Kolibash, A. J. Jr et al. Evidence for progression from mild to severe mitral regurgitation in mitral valve prolapse. Am. J. Cardiol. 58, 762-767 (1986).
174. Jimenez, J. H., Soerensen, D. D., He, Z., He, S. & Yoganathan, A. P. Effects of a saddle shaped annulus on mitral valve function and chordal force distribution: an in vitro study. Ann. Biomed. Eng. 31, 1171-1181 (2003).
175. Hagler, M. A. et al. TGF-beta signalling and reactive oxygen species drive fibrosis and matrix remodelling in myxomatous mitral valves. Cardiovasc. Res. 99, 175-184 (2013).
176. Hulin, A. et al. Emerging pathogenic mechanisms in human myxomatous mitral valve: lessons from past and novel data. Cardiovasc. Pathol. 22, 245-250 (2013).
177. Sainger, R. et al. Human myxomatous mitral valve prolapse: role of bone morphogenetic protein 4 in valvular interstitial cell activation. J. Cell Physiol. 227, 2595-2604 (2012).
178. Madsen, M. B. et al. Identification of 2 loci associated with development of myxomatous mitral valve disease in Cavalier King Charles Spaniels. J. Hered. 102 (Suppl. 1), S62-S67 (2011).
179. Obayashi, K. et al. Effects of transforming growth factor-beta3 and matrix metalloproteinase-3 on the pathogenesis of chronic mitral valvular disease in dogs. Am. J. Vet. Res. 72, 194-202 (2011).
180. Spirito, P. & Maron, B. J. Patterns of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: assessment by two-dimensional echocardiography. Am. J. Cardiol. 54, 1039-1046 (1984).
181. Maron, M. S. et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med. 348, 295-303 (2003).
182. Maron, M. S. et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114, 2232-2239 (2006).
183. Maron, B. J. & Epstein, S. E. Hypertrophic cardiomyopathy. Recent observations regarding the specificity of three hallmarks of the disease: asymmetric septal hypertrophy, septal disorganization and systolic anterior motion of the anterior mitral leaflet. Am. J. Cardiol. 45, 141-154 (1980).
184. Levine, R. A., Schwammenthal, E. & Song, J. K. Diastolic leading to systolic anterior motion: new technology reveals physiology. J. Am. Coll. Cardiol. 64, 1996-1999 (2014).
185. Jiang, L., Levine, R. A., King, M. E. & Weyman, A. E. An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. Am. Heart J. 113, 633-644 (1987).
186. Lefebvre, X. P., He, S., Levine, R. A. & Yoganathan, A. P. Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: an in vitro pulsatile flow study. J. Heart Valve Dis. 4, 422-438 (1995).
187. Levine, R. A. et al. Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction. Circulation 91, 1189-1195 (1995).
188. Sherrid, M. V., Gunsburg, D. Z., Moldenhauer, S. & Pearle, G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 36, 1344-1354 (2000).
189. Cape, E. G. et al. Chordal geometry determines the shape and extent of systolic anterior mitral motion: in vitro studies. J. Am. Coll. Cardiol. 13, 1438-1448 (1989).
190. Nakatani, S. et al. New insights into the reduction of mitral valve systolic anterior motion after ventricular septal myectomy in hypertrophic obstructive cardiomyopathy. Am. Heart J. 131, 294-300 (1996).
191. Yoganathan, A. P., Lemmon, J. D. Jr, Kim, Y. H., Levine, R. A. & Vesier, C. C. A three-dimensional computational investigation of intraventricular fluid dynamics: examination into the initiation of systolic anterior motion of the mitral valve leaflets. J. Biomech. Eng. 117, 94-102 (1995).
192. Maron, B. J., Harding, A. M., Spirito, P., Roberts, W. C. & Waller, B. F. Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy. Circulation 68, 282-293 (1983).
193. Delling, F. N. et al. Frequency and mechanism of persistent systolic anterior motion and mitral regurgitation after septal ablation in obstructive hypertrophic cardiomyopathy. Am. J. Cardiol. 100, 1691-1695 (2007).
194. Kaple, R. K. et al. Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes. Ann. Thorac. Surg. 85, 1527-1535.e2 (2008).
195. Bryant, R. 3rd & Smedira, N. G. Papillary muscle realignment for symptomatic left ventricular outflow tract obstruction. J. Thorac. Cardiovasc. Surg. 135, 223-224 (2008).
196. McIntosh, C. L., Maron, B. J., Cannon, R. O. 3rd & Klues, H. G. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation 86 (Suppl. II), II60-II67 (1992).
197. Ross, R. E., Sherrid, M. V., Casey, M. M., Swistel, D. G. & Balaram, S. K. Does surgical relief of obstruction improve prognosis for hypertrophic cardiomyopathy Prog. Cardiovasc. Dis. 54, 529-534 (2012).
198. Schwammenthal, E. & Levine, R. A. Dynamic subaortic obstruction: a disease of the mitral valve suitable for surgical repair J. Am. Coll. Cardiol. 28, 203-20 (1996).
199. Seeburger, J., Passage, J., Borger, M. A. & Mohr, F. W. A new concept for correction of systolic anterior motion and mitral valve regurgitation in patients with hypertrophic obstructive cardiomyopathy. J. Thorac. Cardiovasc. Surg. 140, 481-483 (2010).
200. van der Lee, C., Kofflard, M. J., van Herwerden, L. A., Vletter, W. B. & ten Cate, F. J. Sustained improvement after combined anterior mitral leaflet extension and myectomy in hypertrophic obstructive cardiomyopathy. Circulation 108, 2088-2092 (2003).
201. He, S. et al. Importance of leaflet elongation in causing systolic anterior motion of the mitral valve. J. Heart Valve Dis. 6, 149-159 (1997).
202. Klues, H. G., Roberts, W. C. & Maron, B. J. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation 84, 1188-1197 (1991).
203. Musumeci, B., Spirito, P., Parodi, M. I., Assenza, G. E. & Autore, C. Congenital accessory mitral valve tissue anomaly in a patient with genetically confirmed hypertrophic cardiomyopathy. J. Am. Soc. Echocardiogr. 24, 592.e5-e6 (2011).
204. Zhu, W. X., Oh, J. K., Kopecky, S. L., Schaff, H. V. & Tajik, A. J. Mitral regurgitation due to ruptured chordae tendineae in patients with hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 20, 242-247 (1992).
205. Petrone, R. K., Klues, H. G., Panza, J. A., Peterson, E. E. & Maron, B. J. Coexistence of mitral valve prolapse in a consecutive group of 528 patients with hypertrophic cardiomyopathy assessed with echocardiography. J. Am. Coll. Cardiol. 20, 55-61 (1992).
206. Maron, M. S. et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 124, 40-47 (2011).
207. Klues, H. G., Roberts, W. C. & Maron, B. J. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation 87, 1570-1579 (1993).
208. Jebara, V. A. et al. Left ventricular outflow tract obstruction after mitral valve repair. Results of the sliding leaflet technique. Circulation 88 (Suppl. II), II30-II34 (1993).
209. Klues, H. G., Maron, B. J., Dollar, A. L. & Roberts, W. C. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 85, 1651-1660 (1992).
210. Hagege, A. A. et al. Familial hypertrophic cardiomyopathy. Cardiac ultrasonic abnormalities in genetically affected subjects without echocardiographic evidence of left ventricular hypertrophy. Eur. Heart J. 19, 490-499 (1998).
211. Nematalla, H. et al. Targeted Mybpc3 knock-out mice with non-obstructive hypertrophic cardiomyopathy exhibit structural mitral valve abnormalities [abstract]. J. Am. Coll. Cardiol. 57, E1397 (2011).
212. Dal-Bianco, J. P. et al. Active adaptation of the tethered mitral valve: insights into a compensatory mechanism for functional mitral regurgitation. Circulation 120, 334-342 (2009).
213. Butcher, J. T. & Markwald, R. R. Valvulogenesis: the moving target. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 362, 1489-1503 (2007).
214. Olivotto, I., Cecchi, F., Poggesi, C. & Yacoub, M. H. Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. Nat. Rev. Cardiol. 6, 317-321 (2009).
215. Gittenberger-de Groot, A. C., Vrancken Peeters, M. P., Mentink, M. M., Gourdie, R. G. & Poelmann, R. E. Epicardium-derived cells contribute a novel population to the myocardial wall and the atrioventricular cushions. Circ. Res. 82, 1043-1052 (1998).
216. Prabhakar, R. et al. A mouse model of familial hypertrophic cardiomyopathy caused by a alpha-tropomyosin mutation. Mol. Cell Biochem. 251, 33-42 (2003).
217. Rajan, S. et al. Microarray analysis of gene expression during early stages of mild and severe cardiac hypertrophy. Physiol. Genomics 27, 309-317 (2006).
218. Teekakirikul, P. et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J. Clin. Invest. 120, 3520-3529 (2010).
219. Niu, Z. et al. Serum response factor orchestrates nascent sarcomerogenesis and silences the biomineralization gene program in the heart. Proc. Natl Acad. Sci. USA 105, 17824-17829 (2008).
220. Norris, R. A. et al. Identification and detection of the periostin gene in cardiac development. Anat. Rec. A. Discov. Mol. Cell. Evol. Biol. 281, 1227-1233 (2004).
221. Levine, R. A. & Hung, J. Ischemic mitral regurgitation, the dynamic lesion: clues to the cure. J. Am. Coll. Cardiol. 42, 1929-1932 (2003).
222. Godley, R. W., Wann, L. S., Rogers, E. W., Feigenbaum, H. & Weyman, A. E. Incomplete mitral leaflet closure in patients with papillary muscle dysfunction. Circulation 63, 565-571 (1981).
223. Otsuji, Y. et al. Mechanism of ischemic mitral regurgitation with segmental left ventricular dysfunction: three-dimensional echocardiographic studies in models of acute and chronic progressive regurgitation. J. Am. Coll. Cardiol. 37, 641-648 (2001).
224. Otsuji, Y. et al. Insights from three-dimensional echocardiography into the mechanism of functional mitral regurgitation: direct in vivo demonstration of altered leaflet tethering geometry. Circulation 96, 1999-2008 (1997).
225. Yiu, S. F., Enriquez-Sarano, M., Tribouilloy, C., Seward, J. B. & Tajik, A. J. Determinants of the degree of functional mitral regurgitation in patients with systolic left ventricular dysfunction: A quantitative clinical study. Circulation 102, 1400-1406 (2000).
226. Kalra, K. et al. Temporal changes in interpapillary muscle dynamics as an active indicator of mitral valve and left ventricular interaction in ischemic mitral regurgitation. J. Am. Coll. Cardiol. 64, 1867-1879 (2014).
227. Otsuji, Y. et al. Isolated annular dilation does not usually cause important functional mitral regurgitation: comparison between patients with lone atrial fibrillation and those with idiopathic or ischemic cardiomyopathy. J. Am. Coll. Cardiol. 39, 1651-1656 (2002).
228. Meris, A. et al. Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. J. Am. Soc. Echocardiogr. 25, 535-542 (2012).
229. Beaudoin, J. et al. Severe ischemic mitral regurgitation despite normally contracting subpapillary myocardium. Circulation 126, 138-141 (2012).
230. Chinitz, J. S. et al. Mitral apparatus assessment by delayed enhancement CMR: relative impact of infarct distribution on mitral regurgitation. JACC Cardiovasc. Imaging 6, 220-234 (2013).
231. Gorman, J. H. 3rd et al. Infarct size and location determine development of mitral regurgitation in the sheep model. J. Thorac. Cardiovasc. Surg. 115, 615-622 (1998).
232. Kumanohoso, T. et al. Mechanism of higher incidence of ischemic mitral regurgitation in patients with inferior myocardial infarction: quantitative analysis of left ventricular and mitral valve geometry in 103 patients with prior myocardial infarction. J. Thorac. Cardiovasc. Surg. 125, 135-143 (2003).
233. Yosefy, C. et al. Mitral regurgitation after anteroapical myocardial infarction: new mechanistic insights. Circulation 123, 1529-1536 (2011).
234. Kim, K. et al. Mechanism of asymmetric leaflet tethering in ischemic mitral regurgitation: 3D analysis with multislice CT. JACC Cardiovasc. Imaging 5, 230-232 (2012).
235. Ryan, L. P. et al. Mitral valve tenting index for assessment of subvalvular remodeling. Ann. Thorac. Surg. 84, 1243-1249 (2007).
236. Padala, M., Gyoneva, L. I., Thourani, V. H. & Yoganathan, A. P. Impact of mitral valve geometry on hemodynamic efficacy of surgical repair in secondary mitral regurgitation. J. Heart Valve Dis. 23, 79-87 (2014).
237. Zeng, X. et al. Asymmetric versus symmetric tethering patterns in ischemic mitral regurgitation: geometric differences from three-dimensional transesophageal echocardiography. J. Am. Soc. Echocardiogr. 27, 367-375 (2014).
238. Barzilai, B., Gessler, C. Jr, Perez, J. E., Schaab, C. & Jaffe, A. S. Significance of Doppler-detected mitral regurgitation in acute myocardial infarction. Am. J. Cardiol. 61, 220-223 (1988).
239. Grigioni, F. et al. Contribution of ischemic mitral regurgitation to congestive heart failure after myocardial infarction. J. Am. Coll. Cardiol. 45, 260-267 (2005).
240. Grigioni, F., Enriquez-Sarano, M., Zehr, K. J., Bailey, K. R. & Tajik, A. J. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 103, 1759-1764 (2001).
241. Lamas, G. A. et al. Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circulation 96, 827-833 (1997).
242. Okura, H. et al. Functional mitral regurgitation predicts prognosis independent of left ventricular systolic and diastolic indices in patients with ischemic heart disease. J. Am. Soc. Echocardiogr. 21, 355-360 (2008).
243. Tcheng, J. E. et al. Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. Ann. Intern. Med. 117, 18-24 (1992).
244. Szymanski, C. et al. Impact of mitral regurgitation on exercise capacity and clinical outcomes in patients with ischemic left ventricular dysfunction. Am. J. Cardiol. 108, 1714-1720 (2011).
245. Beeri, R. et al. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ. Heart Fail. 3, 627-634 (2010).
246. Beeri, R. et al. Early repair of moderate ischemic mitral regurgitation reverses left ventricular remodeling: a functional and molecular study. Circulation 116 (Suppl. I), I288-I293 (2007).
247. Beeri, R. et al. Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J. Am. Coll. Cardiol. 51, 476-486 (2008).
248. Beaudoin, J. et al. Late repair of ischemic mitral regurgitation does not prevent left ventricular remodeling: importance of timing for beneficial repair. Circulation 128, S248-S252 (2013).
249. Soleimani, M. et al. Moderate mitral regurgitation accelerates left ventricular remodeling after posterolateral myocardial infarction. Ann. Thorac. Surg. 92, 1614-1620 (2011).
250. Hung, J. et al. Mechanism of recurrent ischemic mitral regurgitation after annuloplasty: continued LV remodeling as a moving target. Circulation 110 (Suppl. II), II85-II90 (2004).
251. Levine, R. A., Messas, E., Nathan, N. S. & Rudski, L. G. New understanding of ischemic mitral regurgitation: the marionette and its masters. Eur. J. Echocardiogr. 5, 313-317 (2004).
252. Qin, J. X. et al. Importance of mitral valve repair associated with left ventricular reconstruction for patients with ischemic cardiomyopathy: a real-time three-dimensional echocardiographic study. Circulation 108 (Suppl. II), II241-II246 (2003).
253. Levine, R. A. Dynamic mitral regurgitation-more than meets the eye. N. Engl. J. Med. 351, 1681-1684 (2004).
254. Lancellotti, P., Lebrun, F. & Pierard, L. A. Determinants of exercise-induced changes in mitral regurgitation in patients with coronary artery disease and left ventricular dysfunction. J. Am. Coll. Cardiol. 42, 1921-1928 (2003).
255. Lancellotti, P., Troisfontaines, P., Toussaint, A. C. & Pierard, L. A. Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction. Circulation 108, 1713-1717 (2003).
256. Sheikh, K. H., Bengtson, J. R., Rankin, J. S., de Bruijn, N. P. & Kisslo, J. Intraoperative transesophageal Doppler color flow imaging used to guide patient selection and operative treatment of ischemic mitral regurgitation. Circulation 84, 594-604 (1991).
257. Grewal, K. S. et al. Effect of general anesthesia on the severity of mitral regurgitation by transesophageal echocardiography. Am. J. Cardiol. 85, 199-203 (2000).
258. Tei, C., Horikiri, Y., Park, J. C., Jeong, J. W., Chang, K. S., Toyama, Y. & Tanaka, N. Acute hemodynamic improvement by thermal vasodilation in congestive heart failure. Circulation 91, 2582-2590 (1995).
259. Pierard, L. A. & Lancellotti, P. The role of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema. N. Engl. J. Med. 351, 1627-1634 (2004).
260. Lancellotti, P. et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging 14, 611-644 (2013).
261. Grossi, E. A. et al. Late results of isolated mitral annuloplasty for "functional" ischemic mitral insufficiency. J. Card. Surg. 16, 328-332 (2001).
262. McGee, E. C. et al. Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation. J. Thorac. Cardiovasc. Surg. 128, 916-924 (2004).
263. Cheng, A. et al. Undersized mitral annuloplasty inhibits left ventricular basal wall thickening but does not affect equatorial wall cardiac strains. J. Heart Valve Dis. 16, 349-358 (2007).
264. Acker, M. A. et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N. Engl. J. Med. 370, 23-32 (2014).
265. Kron, I. L., Green, G. R. & Cope, J. T. Surgical relocation of the posterior papillary muscle in chronic ischemic mitral regurgitation. Ann. Thorac. Surg. 74, 600-601 (2002).
266. Zhu, F. et al. Mechanism of persistent ischemic mitral regurgitation after annuloplasty: importance of augmented posterior mitral leaflet tethering. Circulation 112 (Suppl. I), I396-I401 (2005).
267. Kubota, K. et al. Functional mitral stenosis after surgical annuloplasty for ischemic mitral regurgitation: importance of subvalvular tethering in the mechanism and dynamic deterioration during exertion. J. Thorac. Cardiovasc. Surg. 140, 617-623 (2010).
268. Bertrand, P. B. et al. Mitral valve area during exercise after restrictive mitral valve annuloplasty: importance of diastolic anterior leaflet tethering. J. Am. Coll. Cardiol. 65, 452-461 (2015).
269. Schwammenthal, E. Undersized and overstretched: mitral mechanics after restrictive annuloplasty. J. Am. Coll. Cardiol. 65, 462-464 (2015).
270. Langer, F. et al. Subvalvular repair: the key to repairing ischemic mitral regurgitation Circulation 112 (Suppl. I), I383-I389 (2005).
271. Einstein, D. R. et al. Fluid-structure interactions of the mitral valve and left heart: comprehensive strategies, past, present and future. Int. J. Numer. Methods Eng. 26, 348-380 (2010).
272. Kunzelman, K. S., Reimink, M. S. & Cochran, R. P. Annular dilatation increases stress in the mitral valve and delays coaptation: a finite element computer model. Cardiovasc. Surg. 5, 427-434 (1997).
273. Wenk, J. F. et al. First finite element model of the left ventricle with mitral valve: insights into ischemic mitral regurgitation. Ann. Thorac. Surg. 89, 1546-1553 (2010).
274. Calafiore, A. M. et al. Echocardiographically based treatment of chronic ischemic mitral regurgitation. J. Thorac. Cardiovasc. Surg. 141, 1150-1156e1 (2011).
275. Hung, J. et al. Reverse ventricular remodeling reduces ischemic mitral regurgitation: echo-guided device application in the beating heart. Circulation 106, 2594-2600 (2002).
276. Messas, E. et al. Relief of mitral leaflet tethering following chronic myocardial infarction by chordal cutting diminishes left ventricular remodeling. Circ. Cardiovasc. Imaging 3, 679-686 (2010).
277. Moainie, S. L. et al. Infarct restraint attenuates remodeling and reduces chronic ischemic mitral regurgitation after postero-lateral infarction. Ann. Thorac. Surg. 74, 444-449 (2002).
278. Szymanski, C. et al. Comprehensive annular and subvalvular repair of chronic ischemic mitral regurgitation improves long-term results with the least ventricular remodeling. Circulation 126, 2720-2727 (2012).
279. Hung, J. et al. A novel approach for reducing ischemic mitral regurgitation by injection of a polymer to reverse remodel and reposition displaced papillary muscles. Circulation 118, S263-S269 (2008).
280. Hung, J. et al. Persistent reduction of ischemic mitral regurgitation by papillary muscle repositioning: structural stabilization of the papillary muscle-ventricular wall complex. Circulation 116 (Suppl. I), I259-I263 (2007).
281. Liel-Cohen, N. et al. Design of a new surgical approach for ventricular remodeling to relieve ischemic mitral regurgitation: insights from 3-dimensional echocardiography. Circulation 101, 2756-2763 (2000).
282. Solis, J. et al. Polymer injection therapy to reverse remodel the papillary muscles: efficacy in reducing mitral regurgitation in a chronic ischemic model. Circ. Cardiovasc. Interven. 3, 499-505 (2010).
283. Langer, F. & Schafers, H. J. RING plus STRING: papillary muscle repositioning as an adjunctive repair technique for ischemic mitral regurgitation. J. Thorac. Cardiovasc. Surg. 133, 247-249 (2007).
284. Wakiyama, H. et al. Chordal cutting for the treatment of ischemic mitral regurgitation: two case reports [Japanese]. J. Cardiol. 44, 113-117 (2004).
285. Messas, E. et al. Chordal cutting: a new therapeutic approach for ischemic mitral regurgitation. Circulation 104, 1958-1963 (2001).
286. Messas, E. et al. Efficacy of chordal cutting to relieve chronic persistent ischemic mitral regurgitation. Circulation 108 (Suppl. II), II111-II115 (2003).
287. Messas, E. et al. Chordal cutting does not adversely affect left ventricle contractile function. Circulation 114 (Suppl. I), I524-I528 (2006).
288. Yamamoto, H., Iguro, Y., Sakata, R., Arata, K. & Yotsumoto, G. Effectively treating ischemic mitral regurgitation with chordal cutting in combination with ring annuloplasty and left ventricular reshaping approach. J. Thorac. Cardiovasc. Surg. 130, 589-590 (2005).
289. Borger, M. A. et al. Initial results of the chordal-cutting operation for ischemic mitral regurgitation. J. Thorac. Cardiovasc. Surg. 133, 1483-1492 (2007).
290. Jassar, A. S. et al. Posterior leaflet augmentation in ischemic mitral regurgitation increases leaflet coaptation and mobility. Ann. Thorac. Surg. 94, 1438-1445 (2012).
291. Kanzaki, H. et al. A mechanism for immediate reduction in mitral regurgitation after cardiac resynchronization therapy: insights from mechanical activation strain mapping. J. Am. Coll. Cardiol. 44, 1619-1625 (2004).
292. Smith, P. K. et al. Surgical treatment of moderate ischemic mitral regurgitation. N. Engl. J. Med. 371, 2178-2188 (2014).
293. Volo, S. C. et al. Effect of myocardial perfusion pattern on frequency and severity of mitral regurgitation in patients with known or suspected coronary artery disease. Am. J. Cardiol. 114, 355-361 (2014).
294. Nielsen, S. L. et al. Mechanism of incomplete mitral leaflet coaptation-interaction of chordal restraint and changes in mitral leaflet coaptation geometry. Insight from in vitro validation of the premise of force equilibrium. J. Biomech. Eng. 124, 596-608 (2002).
295. Stephens, E. H., Chu, C.-K. & Grande-Allen, K. J. Valve proteoglycan content and glycosaminoglycan fine structure are unique to microstructure, mechanical load and age: Relevance to an age-specific tissue-engineered heart valve. Acta Biomater. 4, 1148-1160 (2008).
296. Timek, T. A. et al. Mitral leaflet remodeling in dilated cardiomyopathy. Circulation 114 (Suppl. I), I518-I523 (2006).
297. Kunzelman, K. S., Quick, D. W. & Cochran, R. P. Altered collagen concentration in mitral valve leaflets: biochemical and finite element analysis. Ann. Thorac. Surg. 66, S198-S205 (1998).
298. Quick, D. W., Kunzelman, K. S., Kneebone, J. M. & Cochran, R. P. Collagen synthesis is upregulated in mitral valves subjected to altered stress. ASAIO J. 43, 181-186 (1997).
299. Carceller-Blanchard, A. M. & Fouron, J. C. Determinants of the Doppler flow velocity profile through the mitral valve of the human fetus. Br. Heart J. 70, 457-460 (1993).
300. Schoen, F. J. Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering. Circulation 118, 1864-1880 (2008).
301. Rausch, M. K., Tibayan, F. A., Miller, D. C. & Kuhl, E. Evidence of adaptive mitral leaflet growth. J. Mech. Behav. Biomed. Mater. 15, 208-217 (2012).
302. Stephens, E. H. et al. Significant changes in mitral valve leaflet matrix composition and turnover with tachycardia-induced cardiomyopathy. Circulation 120, S112-S119 (2009).
303. Saito, K. et al. Influence of chronic tethering of the mitral valve on mitral leaflet size and coaptation in functional mitral regurgitation. JACC Cardiovasc. Imaging 5, 337-345 (2012).
304. Wylie-Sears, J., Aikawa, E., Levine, R. A., Yang, J. H. & Bischoff, J. Mitral valve endothelial cells with osteogenic differentiation potential. Arterioscl. Thromb. Vasc. Biol. 31, 598-607 (2011).
305. Grande-Allen, K. J. et al. Apparently normal mitral valves in patients with heart failure demonstrate biochemical and structural derangements: an extracellular matrix and echocardiographic study. J. Am. Coll. Cardiol. 45, 54-61 (2005).
306. Beaudoin, J. et al. Mitral valve enlargement in chronic aortic regurgitation as a compensatory mechanism to prevent functional mitral regurgitation in the dilated left ventricle. J. Am. Coll. Cardiol. 61, 1809-1816 (2013).
307. Enriquez-Sarano, M. et al. Valve repair improves the outcome of surgery for mitral regurgitation. A multivariate analysis. Circulation 91, 1022-1028 (1995).
308. Gillam, L. D., Marcoff, L. & Shames, S. Timing of surgery in valvular heart disease: prophylactic surgery vs watchful waiting in the asymptomatic patient. Can. J. Cardiol. 30, 1035-1045 (2014).
309. Kuwahara, E. et al. Mechanism of recurrent/persistent ischemic/functional mitral regurgitation in the chronic phase after surgical annuloplasty: importance of augmented posterior leaflet tethering. Circulation 114 (Suppl. I), I529-I534 (2006).
310. Agricola, E. et al. Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction. Eur. J. Heart Fail. 11, 581-587 (2009).
311. Kizilbash, A. M., Willett, D. L., Brickner, M. E., Heinle, S. K. & Grayburn, P. A. Effects of afterload reduction on vena contracta width in mitral regurgitation. J. Am. Coll. Cardiol. 32, 427-431 (1998).
312. Pu, M., Gao, Z., Pu, D. K. & Davidson, W. R. Jr. Effects of early, late, and long-term nonselective beta-blockade on left ventricular remodeling, function, and survival in chronic organic mitral regurgitation. Circ. Heart Fail. 6, 756-762 (2013).
313. Borer, J. S. Mitral regurgitation: has another magic bullet bitten the dust Circ. Heart Fail. 6, 624-626 (2013).
314. Eldadah, Z. A. et al. The benefit of upgrading chronically right ventricle-paced heart failure patients to resynchronization therapy demonstrated by strain rate imaging. Heart Rhythm 3, 435-442 (2006).
315. Ypenburg, C. et al. Acute effects of initiation and withdrawal of cardiac resynchronization therapy on papillary muscle dyssynchrony and mitral regurgitation. J. Am. Coll. Cardiol. 50, 2071-2077 (2007).
316. Nury, D., Neri, T. & Puceat, M. Human embryonic stem cells and cardiac cell fate. J. Cell Physiol. 218, 455-459 (2009).
317. Leschik, J., Stefanovic, S., Brinon, B. & Puceat, M. Cardiac commitment of primate embryonic stem cells. Nat. Protoc. 3, 1381-1387 (2008).
318. Ferreira, L. S. et al. Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle like cells and form vascular networks in vivo. Circ. Res. 101, 286-294 (2007).